International Journal of Medical and Pharmaceutical Research
2023, Volume-4, Issue-2 doi: 10.5281/zenodo.7847874
Original Article
Evaluation of Nebulised Dexmedetomidine in Blunting Haemodynamic Response to Laryngoscopy and Intubation: Tertiary Care Centre
 ,
 ,
Published
April 20, 2023
Abstract
Introduction: The process of laryngoscopy and endotracheal tube intubation causes immense sympathetic system activation which further causes intra-operative complications. In high risk patients, this pressor response can increase morbidity and mortality. Dexmedetomidine has good bioavailability and rapid absorption through nasal mucosa so this study evaluates effects of nebulised dexmedetomidine in blunting haemodynamic response to laryngoscopy and intubation. Material and methods: Analytical study was conducted in 100 ASA 1&2 patients. Study population was divided randomly into 2 groups. Control group B(n=50)received nebulisation with 5ml of normal saline and Study group A(n=50)received 1mics/kg dexmedetomidine in 5ml saline 10min before induction in sitting position. Results: Demographics are compared. Following laryngoscopy and intubation SBP, DBP, MAP, HR showed significant increase in control group B as compared to study group A. There was a dose sparing effect of propofol in group A. Conclusion: Nebulised dexmedetomidine effectively blunts the stress response to laryngoscopy and intubation with no adverse effects.
Recommended Articles
Loading Image...
Volume-4, Issue-2
Citations
898 Views
67 Downloads
Share this article
License
Copyright (c) International Journal of Medical and Pharmaceutical Research
pdf Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All papers should be submitted electronically. All submitted manuscripts must be original work that is not under submission at another journal or under consideration for publication in another form, such as a monograph or chapter of a book. Authors of submitted papers are obligated not to submit their paper for publication elsewhere until an editorial decision is rendered on their submission. Further, authors of accepted papers are prohibited from publishing the results in other publications that appear before the paper is published in the Journal unless they receive approval for doing so from the Editor-In-Chief.
IJMPR open access articles are licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. This license lets the audience to give appropriate credit, provide a link to the license, and indicate if changes were made and if they remix, transform, or build upon the material, they must distribute contributions under the same license as the original.
Logo
International Journal of Medical and Pharmaceutical Research
About Us
The International Journal of Medical and Pharmaceutical Research (IJMPR) is an EMBASE (Elsevier)–indexed, open-access journal for high-quality medical, pharmaceutical, and clinical research.
Follow Us
© Copyright IJMPR | All Rights Reserved